Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
Recruiting · NCT07393672 · Interventional (participants receive a specific treatment) · Lead sponsor: Washington State University
View the official record on ClinicalTrials.gov →Interventions studied
Hemp-derived cannabinoidsPlacebo
What this trial is about
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Who can take part
Age range
40 Years to 60 Years
Sex
Female
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- designated female at birth
- 40-60 years of age
- able to give informed consent (no intellectual disability)
- stable pharmacotherapeutic regimen, no change in the past 3 months
- abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months
- abstinent for supplements, don't add any supplements (no changes in past 3 months)
- own a smartphone
- have access to Zoom on a secure, stable internet connection
- perimenopausal or menopausal
Exclusion criteria
- currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
- severe depression, neurovegetative symptoms, or current suicidality
- psychosis or family history of psychosis
- pregnant or breastfeeding
- chemotherapy
- hypotension
- drug testing for work or other reasons
- illicit drug use in past 3 months (cannabis not illicit)
- heavy alcohol use (4 drinks more than 4x/week)
- international/air travel planned for more than one week in the next 3 months
- cocounut allergy
Where it is running
1 location listed across 1 US state.
- Washington State University, Dept of Psychology - Pullman, Washington, United States